[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:apol1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"APOL1 Gene",5,4,[8,16,22,27,34],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06830629","A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease",[12],"Phase 2","RECRUITING","2026-08-26T02:18:01.700186Z","2026-07-30T01:46:14.468260Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06500702","A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease",[12],"2026-08-26T02:19:17.380174Z","2026-07-24T01:27:14.871331Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":14,"content_modified":26},"NCT06824987","Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease",[12],"2026-07-05T05:32:16.696233Z",{"nct_id":28,"title":29,"phases":30,"status":13,"updated_at":32,"content_modified":33},"NCT05312879","Phase 2\u002F3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease",[31],"Phase 2\u002FPhase 3","2026-08-26T02:16:31.714843Z","2026-05-05T02:43:28.556766Z",{"nct_id":35,"title":36,"phases":37,"status":38,"updated_at":39,"content_modified":40},"NCT06794996","Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T00:58:58.946605Z","2026-07-05T20:59:06.676789Z"]